Fluidigm’s (NASDAQ:FLDM) new immune profiling system, Maxpar Direct, quantifies immune cell populations with automated five-minute results reporting.
Maxpar Direct uses a single-tube workflow to profile 37 different immune cell populations from whole blood and human peripheral blood mononuclear cells. Improving on Fluidigm’s Maxpar human immune monitoring panel kit, Maxpar Direct offers better workflow and more comprehensive immune cell profile reporting.
Immune profiling is an important part of diagnosing and treating immune-related diseases such as inflammatory and autoimmune diseases, as well as cancer. Fluidigm cites a 30% increase in clinical trials using immune cell profiling in the last two years.
